Toenail Onychomycosis Therapeutics
1. Jublia patent expiration
Treatment: Antimycotic uses, specifically treatment of onychomycosis; Topical treatment of onychomycosis of the toenail(s) due to trichophyton rubrum and trichophyton mentagrophytes; Topical treatment of the toe...
JUBLIA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7214506 | BAUSCH | Method for treating onychomycosis |
Feb, 2026
(a month from now) | |
| US9566272 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jan, 2028
(1 year, 11 months from now) | |
| US9877955 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jan, 2028
(1 year, 11 months from now) | |
| US10512640 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jan, 2028
(1 year, 11 months from now) | |
| US10342875 | BAUSCH | Stabilized efinaconazole compositions |
Oct, 2034
(8 years from now) | |
| US11213519 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jan, 2028
(1 year, 11 months from now) | |
| US10478601 | BAUSCH | Applicator |
Apr, 2035
(9 years from now) | |
| US11654139 | BAUSCH | Anti-infective methods, compositions, and devices |
Oct, 2034
(8 years from now) | |
| US10828293 | BAUSCH | Anti-infective methods, compositions, and devices |
Oct, 2034
(8 years from now) | |
| US10864274 | BAUSCH | Stabilized efinaconazole formulations |
Oct, 2034
(8 years from now) | |
| US11872218 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jan, 2028
(1 year, 11 months from now) | |
| US8039494 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jul, 2030
(4 years from now) | |
| US9662394 | BAUSCH | Stabilized efinaconazole compositions |
Oct, 2034
(8 years from now) | |
| US9861698 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jul, 2030
(4 years from now) | |
| US8486978 | BAUSCH | Compositions and methods for treating diseases of the nail |
Oct, 2030
(4 years from now) | |
| US10105444 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jul, 2030
(4 years from now) | |
| US9302009 | BAUSCH | Compositions and methods for treating diseases of the nail |
Oct, 2030
(4 years from now) | |
| US10828369 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jan, 2028
(1 year, 11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 06, 2019 |
| New Patient Population(NPP) | Apr 27, 2023 |
Drugs and Companies using EFINACONAZOLE ingredient
NCE-1 date: 06 June, 2018
Market Authorisation Date: 06 June, 2014
Dosage: SOLUTION
How can I launch a generic of JUBLIA before it's drug patent expiration?
More Information on Dosage
JUBLIA family patents
2. Kerydin patent expiration
Treatment: Treatment for onychomycosis that is tinea unguium; Treatment of onychomychosis of a toenail caused by trichophyton rubrum or trichophyton mentagrophytes; Treatment of onychomycosis of a toenail
KERYDIN IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9566289 | ANACOR PHARMS INC | Boron-containing small molecules |
Feb, 2026
(a month from now) | |
| US7582621 | ANACOR PHARMS INC | Boron-containing small molecules |
May, 2027
(1 year, 4 months from now) | |
| US9566290 | ANACOR PHARMS INC | Boron-containing small molecules |
Feb, 2026
(a month from now) | |
|
US9566290 (Pediatric) | ANACOR PHARMS INC | Boron-containing small molecules |
Aug, 2026
(7 months from now) | |
|
US9572823 (Pediatric) | ANACOR PHARMS INC | Boron-containing small molecules |
Aug, 2026
(7 months from now) | |
|
US9549938 (Pediatric) | ANACOR PHARMS INC | Boron-containing small molecules |
Aug, 2026
(7 months from now) | |
| US9549938 | ANACOR PHARMS INC | Boron-containing small molecules |
Feb, 2026
(a month from now) | |
| US7767657 | ANACOR PHARMS INC | Boron-containing small molecules |
May, 2027
(1 year, 4 months from now) | |
| US9572823 | ANACOR PHARMS INC | Boron-containing small molecules |
Feb, 2026
(a month from now) | |
|
US9566289 (Pediatric) | ANACOR PHARMS INC | Boron-containing small molecules |
Aug, 2026
(7 months from now) | |
|
US7582621 (Pediatric) | ANACOR PHARMS INC | Boron-containing small molecules |
Nov, 2027
(1 year, 10 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 07, 2019 |
| Pediatric Exclusivity(PED) | Jan 07, 2020 |
Drugs and Companies using TAVABOROLE ingredient
NCE-1 date: 07 January, 2019
Market Authorisation Date: 07 July, 2014
Dosage: SOLUTION
How can I launch a generic of KERYDIN before it's drug patent expiration?
More Information on Dosage
KERYDIN family patents